Smart Immune picks up $5M from Gates Foundation; Oxford Nanopore teams up with French diagnostics player
French biotech Smart Immune has been handed an equity investment of $5 million from the Bill & Melinda Gates Foundation.
The cash will specifically go to advancing a new Phase I/II clinical trial for Smart Immune’s lead asset, called SMART 101. The drug candidate will be used in patients with acute leukemia, with the eventual goal of developing and releasing an HIV-resistant cell therapy product.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters